Sartorius AG, worldwide active biotech company in Germany sartorius.de
Stock exchange Frankfurt Germany XETRA 716563
One stock that just today caught fire is Sartorius AG. Check it out
Friday 10:37 ET Momentum Theme : After tearing through every tier of biotech, speculators now moving into the biopharmaceutical stocks. Issues participating in momentum theme include: Magainin Pharmaceuticals (MAGN 9 1/2 +3 1/4), Aviron (AVIR 46 1/8 +6 13/32), AutoImmune (AIMM 4 7/8 +1 13/16), Inkine Pharmaceutical (INKP 8 5/8 +5/8) and Scios (SCIO 9
Friday 10:05 ET Biotech Movers : The following biotech names rallying to new session highs: Gene Logic (GLGC 129 1/2 +27 3/8), Ribozyme Pharmaceuticals (RZYM 39 3/8 +5 11/16), LJL BioSystem (LJLB 33 +3 5/8), EntreMed (ENMD 67 29/32 +5 11/32).
Ratings Key: 1. Outperform 2. Slightly Outperform 3. Market Performer 4. Slightly Underperform 5. Underperform. Note: A split rating, such as 3/2, refers to a 3 for short-term and 2 for long-term. It is used under special circumstances.
Revisions Key: N/new, +/upgraded, =/unchanged, -/downgraded
MEDICAL, BIO....2/1..........12/21...........(+)
Comment: It's been a topsy-turvy year for the biotech sector as it has run hot, then cold, then hot again... With many of the stocks having enjoyed good runs in recent weeks, the group appears a bit overextended from a short-term perspective... Then again, this isn't a sector generally geared for short-term traders as the pay-off on many of the drugs/therapies in clinical testing are years away... And with the volume of drugs/therapies now in the clinical testing stage having ramped up significantly over the past couple of years, the long-term outlook for this relatively young industry has never been better... Add to the ever expanding drug / therapy pipeline, a more favorable regulatory environment, industry consolidation, collaborations, relatively strong financials (due to collaboration model), and advancements in drug development methods which reduce cost and increase number of potential new herapies / drugs, and we can help but get excited about the group's potential. Recognizing the short-term valuation risk, Briefing.com maintains its near-term rating of 2 but we are bumping up our long-term rating from 2 to 1. Stocks:Affymetrix (AFFX), Amgen (AMGN), Biogen (BGEN), Cell Genesys (CEGE), Cephalon (CEPH), Chiron (CHIR), Cor Therapeutics (CORR), Gene Logic (GLGC), Genentech (DNA), Genzyme (GENZ), Human Genome Sciences (HGSI), ICOS Corp (ICOS), Idexx (IDXX), Immunex (IMNX), Incyte Pharmaceuticals (INCY), Isis Pharmaceuticals (ISIP), Ligand Pharmaceuticals (LGND), Liposome (LIPO), Millennium (MLNM), Myriad Genetics (MYGN), Scios Inc. (SCIO), Vical (VICL).
Source: www.briefing.com
Sartorius AG
sartorius.de
Stock exchange Frankfurt Germany XETRA 716563
February 16, 2000:
Sartorius AG Acquires B. Braun Biotech International
Sartorius AG, headquartered in Goettingen, Germany, has acquired 90 percent of the shares of B. Braun Biotech International GmbH (BBI) from B. Braun AG, Melsungen, Germany.
By acquiring B. Braun Biotech International GmbH, Sartorius has gained the leading supplier worldwide forfermentation products. Fermentation is a central process step in biotechnology.
As a result, Sartorius has decisively expanded its range of performance products in biotechnology, which is an important growth market. Sartorius now offers comprehensive product solutions for this sector. In addition, the acquisition of BBI has significantly improved
Sartorius' international positioning, particularly in the fast growing market of North America.
In the business years of 1998/1999, BBI reported annual net sales of nearly 100 million DEM on a subgroup basis. Approximately 40 percent was generated in the U.S., the company's key market.
Besides BBI's headquarters in Melsungen, Germany, it has an additional, fully equipped competence center, including production facilities, in Allentown, Pennsylvania, USA.
This acquisition will make the Sartorius Separation Technology Division one of the most important global suppliers for bioprocessing, with a uniquely wide range of products for all-in-one systems, including validation and service. Vivascience, the Sartorius Group brand, and the "In vitro" brand product line will round off Sartorius' position. Vivascience and "In vitro" products are primarily focused on innovative laboratory scale developments.
Moreover, the integration of BBI in the Sartorius Group will attain a level of consolidation that is unequaled to date for systems and project business activities.
December 14, 1999:
Sartorius Acquires Global Weighing Technologies
Sartorius' largest acquisition so far
Significant expansion of industrial weighing technology
Further Expansion Measures Also Planned for the Separation Technology Division
Sartorius AG, headquartered in Goettingen, Germany, has acquired 100 percent of the shares in Global Weighing Technologies GmbH, called GWT. Based in Hamburg, GWT, which formerly belonged to the Philips Group, is a leading supplier of industrial weighing products. GWT has sales units in China, Hong Kong, Canada, Austria and Spain. Allowing for GWT's additional sales companies that Sartorius plans to acquire in the Year 2000, GWT earned
net sales of 82 million German marks in 1998.
With this fifth acquisition in a row, Sartorius has sustained the systematic implementation of its growth strategy as planned. GWT will significantly strengthen Sartorius' strategic business segment in industrial weighing by contributing its product lines for batching, platform scales, truck scales and "on-board weighing." Through the acquisition of GWT, Sartorius can now compete as an integrated, single-source supplier for product solutions in
the fields of precision and industrial weighing technologies and in separation technology. This will enhance Sartorius' strategically competitive position in the long run.
Effective February 1, 2000, Sartorius will acquire the worldwide sales and marketing rights to the product line of In Vitro Systems & Services GmbH, based in Osterode, Harz, Germany.
In Vitro Systems & Services develops highly innovative life science products in the field of cell cultures for the production of proteins and diagnostic media. This follows Sartorius' acquisition of the British firm Vivascience in June of this year, which has shown highly successful development since that time. The purchase of In Vitro Systems & Services is a further step in the expansion of Sartorius' new life sciences business segment.
New York-based Scaltec Instruments, Inc., a subsidiary of the Sartorius Group, has been renamed Sartorius Environmental Technology (SET). At the same time, this company's office has moved to Dubuque, Iowa, and the general nature of its business has been changed to the
development, preparation and marketing of methods, including production and services, in the field of environmental technology.
This measure reflects the Sartorius Group's efforts to step up its activities in environmental and water separation applications.
In addition, Sartorius AG will incorporate subsidiary sales companies in Argentina, Mexico and Switzerland to further enhance its market position in each of these countries.
At the December 9, 1999, meeting, the Supervisory Board of Sartorius AG approved an investment volume of 138 million German marks (without acquisitions) for the
Sartorius Group in the business year 2000. This sum also provides for the measures involving capacity, structure, quality and products in connection with the expansion of ist production facilities in Goettingen, Germany. This investment budget earmarked for Sartorius, the highest ever in its corporate history, will offer the basis for implementing the in-house part of its growth strategy.
Lutz |
